Kyowa Kirin Co., Ltd.: Familial Hypophosphatemic Rickets trials

The registry lists 22 Familial Hypophosphatemic Rickets studies with Kyowa Kirin Co., Ltd. as lead sponsor. 3 are open to participants now and 8 have results posted.

Phase 1 6Phase 2 7Phase 3 6Phase 4 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A First-in-human Study of KK8123 in Adults With X-linked HypophosphatemiaRecruitingNCT06525636Phase 1/2
• Expanded Access to BurosumabAvailableNCT03775187
• Registry for Patients With X-Linked HypophosphatemiaRecruitingNCT03193476
• Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLHCompletedNCT02915705Phase 3Results posted
• Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)CompletedNCT02750618Phase 2Results posted
• Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)CompletedNCT02537431Phase 3Results posted
• Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)CompletedNCT02526160Phase 3Results posted
• Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)CompletedNCT02312687Phase 2Results posted
• Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)CompletedNCT02163577Phase 2Results posted
• An Extension Study of KRN23 in Adults With X-Linked HypophosphatemiaCompletedNCT01571596Phase 1/2Results posted
• A Repeated Study of KRN23 in Adults With X-Linked HypophosphatemiaCompletedNCT01340482Phase 1/2Results posted
• A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal GrowthCompletedNCT05181839
• Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLHCompletedNCT04842032Phase 4
• Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLHCompletedNCT04842019Phase 4
• A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLHCompletedNCT04819490
• A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaCompletedNCT04308096Phase 3
• Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of AgeCompletedNCT04188964Phase 1/2
• Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLHCompletedNCT03920072Phase 3
• Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian PartnersActive, not recruitingNCT03745521
• A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaCompletedNCT03233126Phase 3
• A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/OsteomalaciaCompletedNCT02181764Phase 1
• A Study of KRN23 in X-linked HypophosphatemiaCompletedNCT00830674Phase 1